CINCINNATI, OH – Siloam Biosciences, Inc., a lab on a chip diagnostic & life sciences company, is pleased to announce the hiring of G. Randall Durnell, PhD, MBA, as the company’s new Vice President of Commercial Operations.

“We are very pleased that Randy has agreed to join our organization. He brings with him an in-depth understanding of our business and the markets we serve,” said Dr. C. H. Ahn, President & CEO of Siloam. “Randy has an exemplary track record in commercialization as well as strategic management.”

Dr. Durnell, is an ideal match for Siloam, having over 30 years of experience in corporate and business development for Fortune 500 companies. He has worked as an executive for such industry leaders as Caliper Life Sciences, Beckman Coulter, Aurora Biosciences (now part of Vertex Pharmaceuticals), and four separate divisions of Thermo Fisher Scientific. His professional achievements include the successful acquisition of PanVera while working in a corporate development role at Aurora Biosciences and also for implementing a strategic plan for Aurora that propelled the company’s rise to the number ten spot on Bloomberg’s “Hot 100 List” and a market cap of $2.3 billion. During his tenure at Aurora he commercialized the Nobel Prize winning GFP technologies for novel assays in neuroscience and cancer. Randy has a background in clinical chemistry as well as graduate degrees in marketing and business.

In hiring Dr. Durnell, Dr. Ahn has specific goals in mind as Siloam enters an important phase in its growth and development. “Randy’s job is to enable, support and grow our strategic business interactions and build international distribution. I am confident that he is the right person to help take us to the next level of performance and profitability,” said Dr. Ahn.

“If belief in yourself and your mission is fundamental to success, then Siloam Biosciences will surely be an acknowledged leader in micro-channel ELISA assays and point of care diagnostics within the next three years,” said Durnell. “The management team currently is made up of experts in their respective fields who can execute, maintain focus, and evolve opportunities better than any other young biotech company I have ever seen.”

Aside from the professional opportunities his appointment will bring, Dr. Durnell is candid about his desire to settle back into his home state of Ohio. “The work ethic and corporate environment in Ohio is exceptional. The culture for biotech development in the Cincinnati area is growing along with the economy. Add to that the high quality of life and the small company culture it offers – that is something I want to be a part of,” said Durnell. “Yet I am most excited about taking Siloam’s point of care and micro channel plate technology to the research, clinical trial, and diagnostic markets and help the company bring new knowledge and health to patients.”

Siloam Biosciences, Inc., employs the power of microfluidics to dramatically improve the performance of immunoassays by incorporating microfluidic technology into existing microtiter plate platforms for research and development and clinical laboratory applications. Siloam also develops multi-analyte, single step, clinical diagnostic point of care tests (POCT) for emergency room use and other clinical settings where point of care testing can improve patient care.

For more information contact Dr. Durnell at rdurnell@siloambio.com or visit www.siloambio.com.